Pharmacoepigenetics of Hepatocellular Carcinoma
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Pharmacogenetics".
Deadline for manuscript submissions: closed (31 July 2020) | Viewed by 347
Special Issue Editors
Interests: surgery; transplantation; surgical oncology; oncology; experimental surgery
Special Issues, Collections and Topics in MDPI journals
Interests: surgery; hepatocellular carcinoma; targeted therapies
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In the past few years, hepatocellular carcinoma has become the most frequent malignant liver disease and the third cause of cancer-related death in Western countries. Despite the introduction of new therapies, treatment outcomes are not encouraging. Τhe prognosis of advanced hepatocellular carcinoma is still dismal, underlying the need for novel effective treatments. In addition to the various risk factors that predispose a person to the development of hepatocellular carcinoma, epigenetic factors also play a functional role in tumor genesis.
On the other hand, rapid and major advances in epigenetics are affecting pharmacology, pharmacogenetics, and pharmacoepigenomics (the application of pharmacoepigenetics in the genome), leading to a new era of treatment possibilities.
The purpose of this Special Issue of the Journal of Personalized Medicine is to target the specific challenges of pharmacoepigenetics and pharmacoepigenomics in the treatment of hepatocellular carcinoma, by identifying the molecular mechanisms of tumor response, considering all the pathways of the regulation of gene expression.
We are inviting submissions of original articles, case reports, and reviews that cover the domain of pharmacoepigenetics of hepatocellular carcinoma, focusing on epigenetic therapies, personalized medicine, and epigenetic biomarkers in drug therapies.
Dr. Christos Damaskos
Dr. Dimitrios Dimitroulis
Dr. Nikolaos Garmpis
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatocellular carcinoma
- pharmacoepigenetics
- epigenomics
- targeted therapy
- personalized medicine
